(2S,4S)-2-N-Tert-Butoxycarbonyl-Sulfamoylamino Methyl-4-Mecaptopyrrolidine-1-Nitrobenzyl-Carboxylate

In multi-kilo campaigns conducted under ICH Q7 GMP for intermediates, the (2S,4S)-4-mercaptopyrrolidine scaffold bearing orthogonal protecting groups—N-Boc, O-nitrobenzyl carbamate, and a sulfamoylamino methyl appendage—is introduced during late-stage fragment coupling of a hepatitis C NS3/4A protease inhibitor candidate. The mercapto functionality is deliberately masked as the p-methoxybenzyl (PMB) thioether until after a copper(I)-mediated azide-alkyne cycloaddition (CuAAC) step, at which point oxidative deprotection with 2.5 equiv of DDQ in CH₂Cl₂/water (9:1 v/v) at 0–4 °C over 3.5 h liberates the free thiol without racemization at C-4 (ee >99.2% monitored by chiral SFC). The orthogonality is critical: the nitrobenzyl carbamate remains intact under these conditions, enabling a subsequent palladium-catalyzed nitro reduction and spontaneous 1,6-elimination that unmasks a secondary amine for final acylation. Residual palladium is controlled to <10 ppm per Ph.Eur. 10.0 via trimercaptotriazine scavenger resin treatment in a jacketed 20-L Büchi reactor with Hastelloy C-22 wetted parts to resist thiol-induced stress corrosion. Process analytical technology (PAT) integration, specifically ReactIR 15 with a diamond ATR probe, tracks the disappearance of the PMB C–S stretch at 670 cm⁻¹. The isolated sulfamoylamino alcohol intermediate is then telescoped into a macrolactamization using HATU/2.0 equiv DIPEA in acetonitrile at 0.05 M concentration, affording the 15-membered macrocyclic core of the active pharmaceutical ingredient after silica gel chromatography with a 76–82% isolated yield over five steps. All waste streams containing nitroaromatic by-products are segregated for dedicated incineration per EU waste code 07 07 04*. This drug substance is subsequently formulated as a 100 mg film-coated tablet for once-daily oral administration, and the synthetic route is registered in a Type II Drug Master File with a detailed elemental impurity risk assessment per ICH Q3D.

Validation of the process at 50 kg scale in a cGMP-compliant facility requires specific control of thiol oxidation during the DDQ-mediated deprotection. Dissolved oxygen in the solvent mixture is maintained below 0.5 mg/L by subsurface nitrogen sparging through a 10 μm sintered metal frit, and the batch is blanketed under 0.2 bar nitrogen overpressure throughout. IPC by Ellman’s assay quantifies free thiol concentration versus disulfide dimer; disulfide content must remain <0.8% area by HPLC to avoid purification burden. The protected (2S,4S)-fragment itself is received as a lyophilized white powder with a specification for water content of <0.3% by Karl Fischer titration (Metrohm 901 Titrando), determined because residual moisture promotes premature nitrobenzyl carbamate hydrolysis during storage at −20 °C in amber glass under argon. Typical batch sizes of the intermediate supplied to the finishing plant are 4–6 kg.

ADC Linker-Payload Construction—Where Does Maleimide Incompatibility Force a Thiol-Ester Bridging Strategy?

The (2S,4S) stereochemistry preorganizes the pyrrolidine ring into a conformation that places the mercapto group and the carbamate-protected amine in a 1,3-diaxial-like orientation, a geometry exploited in the assembly of non-cleavable linker-drug constructs for antibody-drug conjugates (ADCs) targeting HER2-positive breast carcinoma. Traditional maleimidocaproyl-based linkers undergo retro-Michael addition in plasma, leading to payload deconjugation rates of 2–4% per day as quantified by hydrophobic interaction chromatography; this motivated the design of a β-thioester linker where the thiol of the (2S,4S)-pyrrolidine undergoes carbodiimide-mediated coupling with a 21-mer peptide sequence bearing a C-terminal azido-lysine. The reaction is performed in 0.1 M MES buffer pH 6.2 with 3.0 equiv of EDC·HCl and 0.5 equiv of HOBt hydrate, maintaining the temperature at 10 °C to suppress racemization at the α-carbon of the pyrrolidine. The resulting thioester-linked construct is then subjected to strain-promoted azide-alkyne cycloaddition (SPAAC) with a DBCO-functionalized anti-HER2 monoclonal antibody (drug-to-antibody ratio, DAR, targeted at 3.8–4.2). The nitrobenzyl carbamate on the pyrrolidine ring serves as a temporary protecting group for the secondary amine that will eventually anchor a cathepsin-B-cleavable Val-Cit-PABC spacer; it is removed by catalytic hydrogenation over 5% Pd/BaSO₄ (poisoned catalyst to avoid pyrrolidine ring hydrogenolysis) in THF/water at 25 psi H₂ for 2 h.

Process development studies on a 15 L scale at an experienced CDMO identified a critical processing window for the carbodiimide coupling step. If the pH drifts above 6.5, significant thioester hydrolysis competes, dropping the coupling efficiency below 60%; if pH drops below 5.8, the free thiol protonation slows the nucleophilic attack and allows disulfide scrambling to reach 12% of the total area. The optimized protocol uses a Metrohm 902 autotitrator dosing 0.5 N HCl and 0.5 N NaOH in a deadband of ±0.05 pH units, linked to the reactor PLC. The thioester intermediate is purified by 30–50 μm LiChroprep RP-18 flash chromatography with a water/acetonitrile gradient containing 0.05% TFA, and pooling decisions are based solely on analytical SEC (TSKgel G3000SWXL, 7.8 × 300 mm) to exclude aggregates > dimer. The final ADC is formulated at 20 mg/mL in 20 mM histidine, 6% trehalose dihydrate, 0.02% polysorbate 20, pH 5.5, and is subjected to accelerated stability testing at 40 °C/75% RH per ICH Q1A(R2); the percentage of unconjugated payload must stay below 1.5% at the 3-month time point by RP-HPLC with fluorescence detection (λex 495 nm, λem 520 nm).

In a separate configuration, the protected (2S,4S)-pyrrolidine itself is used as a heterobifunctional crosslinker for encapsulating live Saccharomyces cerevisiae cells in a poly(ethylene glycol) diacrylate hydrogel bead matrix for continuous ethanol fermentation. The thiol undergoes Michael addition to acrylate-terminated 8-arm PEG (M_n 20 kDa) at pH 7.8 (phosphate buffer) within 12 minutes under gentle magnetic stirring, while the Boc group preserves the sulfamoylamino methyl amine from reacting prematurely. After cell encapsulation, the hydrogel beads are soaked in 4 N HCl/dioxane for 45 min at 20 °C to cleave the Boc group, and the liberated amine is subsequently functionalized with an N-hydroxysuccinimide ester of a fluorescent pH indicator (SNARF-1) for real-time metabolic imaging via confocal microscopy. The nitrobenzyl carbamate remains stable throughout the acidic treatment and subsequent neutralization to pH 7.2. Bead diameter is controlled between 350–500 μm using a coaxial air-jet droplet generator (Nisco Encapsulation Unit VAR V1) at a nozzle vibration frequency of 1.2 kHz. Cell viability by propidium iodide/SYTO 9 staining remains above 92% post-encapsulation. Published data for this specific configuration is limited to internal feasibility reports from one industrial biotechnology group; however, pilot fermentations in a 5 L Sartorius Biostat B demonstrated stable ethanol productivity of 1.8 g/L·h for 320 h of continuous operation with no detectable leaching of the crosslinker degradation products into the fermentation broth (LC-MS LOD 0.1 ng/mL). The process aligns with the general principles of ISO 20387:2018 for biobanking of living cells, though the final format is an immobilized biocatalyst bead, not a cryovial stock.

Nitroreductase-Responsive Prodrug Monomers for Injectable Poly(β-amino ester) Depot Implants

Hypoxic tumor microenvironments overexpress nitroreductase (NTR) at 2–8-fold higher levels than normoxic tissue, a differential exploited by designing a prodrug monomer in which the nitrobenzyl carbamate of the (2S,4S)-pyrrolidine is reduced in a two-electron process by NTR in the presence of NADPH to generate a hydroxylamine that undergoes rapid 1,6-benzyl elimination, liberating the free secondary amine which subsequently triggers polycondensation with a diacrylate sebacate macromer in situ. The monomer is synthesized at 50 mmol scale in a glovebox under <5 ppm O₂, and the thiol group is first protected as the S-tert-butylthio disulfide to prevent radical quenching during the later photoinitiated polymerization step. Stoichiometry of the nitroreductase activation cascade was verified in a cell-free assay using purified E. coli NfsB enzyme (0.5 μM) with 500 μM NADPH in Tris buffer pH 7.4 at 37 °C; release of the amine was complete within 18 min as monitored by continuous fluorescence of a fluorescamine adduct (λex 390 nm, λem 475 nm). For the implantable formulation, the monomer is dissolved at 18 wt% in a mixture of N-methyl-2-pyrrolidone (60 v/v%) and benzyl benzoate (40 v/v%), sterile-filtered through a 0.22 μm PVDF membrane, and filled into single-use glass syringes (BD Hypak SCF) with a fill volume of 1.2 mL. Upon intratumoral injection into a murine 4T1 xenograft model, the reduction by endogenous NTR initiates the step-growth polymerization that transforms the liquid precursor into a waxy solid within 45–90 min in vivo, as assessed by tactile probing and ex vivo rheometry (G′ reaching 450 kPa at 1 Hz, comparison to day-0 specimens).

Aggregation of the monomer in the solvent system poses a shelf-life challenge. Dynamic light scattering (Malvern Zetasizer Nano ZS) of the formulated syringe stored at 25 °C reveals a slow increase in Z-average size from 6 nm to 38 nm over 14 days, accompanied by a rise in polydispersity index from 0.12 to 0.34. This is attributed to intermolecular disulfide exchange at the S-tert-butylthio group catalyzed by trace thiolates. Addition of 1.5 mol% tris(2-carboxyethyl)phosphine (TCEP) hydrochloride, pre-neutralized with NaOH to pH 6.8, suppresses this aggregation pathway and maintains Z-average size below 10 nm for 56 days under accelerated storage. Sterility testing per USP <71> and endotoxin by LAL per USP <85> (<0.5 EU/mL) are performed on each lot prior to release for in vivo use. A comparison of the drug release profile from the in situ-formed depot versus a pre-formed implant of identical composition (photo-polymerized ex vivo with 365 nm UV at 20 mW/cm² for 8 min under nitrogen) is provided in the table below.

In certain applications, the nitrobenzyl carbamate is selectively cleaved by catalytic transfer hydrogenation in microfluidic continuous-flow reactors to produce the free amine intermediate at rates exceeding 12 g/h with a residence time of 45 seconds. A coiled tube reactor (PFA, 1.0 mm i.d., 8.0 mL internal volume) is packed with 2.5 g of 10% Pd/C (type E101 NOX, particle size 50–70 μm) held in place by stainless-steel frits, and a solution of the protected pyrrolidine (0.35 M) in THF containing 2.0 equiv of ammonium formate is pumped at 0.18 mL/min while the reactor is immersed in an oil bath at 60 °C. Backpressure is regulated at 85 psi via an Equilibar ZF precision back-pressure regulator to maintain a single liquid phase. In-line FTIR at the reactor outlet monitors complete consumption of the nitro asymmetric stretch at 1524 cm⁻¹. The stream is passed through a scavenger cartridge of QuadraSil Thiol resin (1.8 g, 1.2 mmol/g) to capture leached palladium before concentration via a wiped-film evaporator. This continuous hydrogenation protocol reduces the E-factor by 58% relative to the corresponding batch process using 5% Pd/C under balloon hydrogen, primarily due to elimination of additional solvent for catalyst filtration and reduced catalyst loading from 12 mol% to 3.5 mol%. The resin-bound scavenger media is regenerated with 0.1 M L-cysteine in aqueous methanol per manufacturer recommendation. The resulting amine intermediate isolated from the hydrogenator outlet meets a purity specification of ≥98.0% by qNMR using dimethyl sulfone as internal standard, and total palladium is below 5 ppm by ICP-MS after scavenger treatment.

When the Protected Mercaptopyrrolidine Serves as a Chiral Derivatizing Agent for Amino Acid Enantiomer Discrimination by ¹⁹F NMR

Simultaneous determination of D- and L-amino acid enantiomeric excess in complex fermentation broths without chromatographic separation is achieved by coupling the (2S,4S)-pyrrolidine scaffold to a 3,5-bis(trifluoromethyl)phenyl isothiocyanate tag through the free thiol, followed by Boc deprotection and subsequent reaction with the amino acid to be analyzed. In practice, the lyophilized broth residue (equivalent to 200 μL original sample) is redissolved in 600 μL of anhydrous DMF, and 2.0 equiv of the protected pyrrolidine per estimated total free amine is added in the presence of 2.5 equiv of DIPEA. The mixture is stirred under argon at 22 °C for 40 min, then Boc is removed by addition of 300 μL of TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v), after which the liberated sulfamoylamino amine is acylated with the amino acid N-hydroxysuccinimide ester formed in situ. The resulting diastereomeric thiourea derivatives display distinct ¹⁹F chemical shifts for D vs. L enantiomers with a baseline separation of 0.28 ppm at 470 MHz on a Bruker Avance NEO spectrometer equipped with a Prodigy cryoprobe. Quantification limit is 0.3% of the minor enantiomer in the presence of the major, a sensitivity that meets the guidance for control of isomeric impurities in new drug substances per ICH M7(R2) for structural alerts class 3 impurities. The derivatization protocol requires careful exclusion of adventitious water (KF < 30 ppm in DMF) to avoid hydrolysis of the isothiocyanate intermediate; this is ensured by drying the solvent over freshly activated 4 Å molecular sieves for 48 h prior to use.

Cross-contamination risk between fermentation campaigns is assessed by running a blank derivatization (solvent + all reagents, no broth) at the beginning of each analytical sequence; any carryover signal in the −60 to −65 ppm window exceeding 0.05% of the internal standard (α,α,α-trifluorotoluene) triggers a full solvent line flush and needle wash cycle. The derivatizing agent itself is stored as a 0.05 M stock solution in anhydrous DMF in single-use, flame-sealed glass ampoules under argon to prevent thiol oxidation, and each ampoule is used within 6 hours of opening. Inter-day precision for 0.5% spiked D-alanine in L-alanine at the LOD is RSD 8.7% (n=15), intra-day RSD is 3.9% (n=5). The method was cross-validated against an orthogonal HPLC protocol with Crownpak CR-I(+) chiral column (4.0 × 150 mm, 5 μm) at 0.8 mL/min in aqueous HClO₄ pH 1.5, showing correlation coefficient r² = 0.994 across 0.3%–15% enantiomeric excess range.

Incorporation of the (2S,4S)-mercaptopyrrolidine fragment into a polymer backbone for reversible disulfide crosslinking in self-healing polyurethane elastomers used for protective industrial coatings requires precise stoichiometric control of the thiol-to-isocyanate ratio during one-shot bulk polymerization. A prepolymer is first synthesized from poly(tetramethylene ether) glycol (M_n 2000) and isophorone diisocyanate at a NCO:OH ratio of 2.2:1 in a planetary mixer under vacuum (5 mbar) at 85 °C for 3 h. The protected pyrrolidine diol (obtained by reduction of the nitrobenzyl ester to the corresponding alcohol with DIBAL-H at −78 °C in toluene) is then added as the chain extender at 0.22 equivalents relative to the remaining NCO groups, along with 0.03 wt% dibutyltin dilaurate catalyst. The tert-butyloxycarbonyl and nitrobenzylcarbamate groups remain on the polymer backbone throughout the film casting step to suppress premature thiol-disulfide interchange during solvent evaporation. Once the film is dry (thickness 180 ± 20 μm), the Boc groups are cleaved by exposure to gaseous HCl generated from concentrated hydrochloric acid in a closed reactor for 2 h, followed by neutralization with ammonium vapor. The nitrobenzyl carbamate is then removed by UV irradiation at 365 nm (60 mW/cm²) through a quartz window while the film is immersed in pH 6.5 phosphate buffer containing 1 mM glutathione, which simultaneously triggers disulfide metathesis and establishes the dynamic covalent network.

Dynamic mechanical analysis (TA Instruments DMA 850) in tensile mode at 1 Hz and 3 °C/min ramp shows that the fully deprotected film exhibits a stable rubbery plateau modulus of 4.1 MPa from 60 °C to 140 °C. After a scratch is introduced with a 200 μm-radius diamond stylus to a depth of 40% of film thickness, healing at 80 °C for 6 h under nitrogen restores 91% of the original ultimate tensile strength (12.4 MPa vs. 13.6 MPa initial) as measured per ASTM D412-16 (Die C). Critically, healing does not occur if the Boc group has not been removed, confirming that the disulfide exchange is the predominant self-healing mechanism, not chain interdiffusion alone. The coating is applied to abrasive-blasted SA 2.5 carbon steel panels with a target dry film thickness of 150 μm and subjected to salt spray testing per ISO 9227:2022; after 720 h, under-film creep at the scribe is limited to <2.3 mm for the deprotected and healed variant, compared to 6.8 mm for the permanently Boc-protected control that cannot re-equilibrate its network. The sulfamoylamino methyl group contributes to adhesion improvement on metallic substrates through ligand interaction with iron oxide-hydroxide surfaces, as evidenced by a 2.3 N/mm² increase in pull-off adhesion strength (PosiTest AT-A automatic adhesion tester, 20 mm dolly) relative to the non-sulfamoylated analogue.